Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros

C S Zong1, B Poon, J Chen

  • 1Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029-6574.

Journal of Virology
|November 1, 1993
PubMed

Insights

Modifications to the 5' region of the c-ros proto-oncogene are crucial for its oncogenic activation. Deleting sequences upstream of the transmembrane domain enhances transforming activity, highlighting the importance of specific genetic alterations.

Area of Science:

  • Molecular Biology
  • Oncology
  • Virology

Background:

  • The avian sarcoma virus UR2 transforming gene, v-ros, encodes a receptor-like protein tyrosine kinase.
  • v-ros differs from its proto-oncogene, c-ros, through 5' truncation, fusion to viral gag, transmembrane domain alterations, and carboxyl region changes.
  • Understanding these differences is key to deciphering the activation of c-ros's transforming potential.

Purpose of the Study:

  • To investigate the structural basis for the oncogenic activation of the c-ros proto-oncogene.
  • To analyze the biological and biochemical properties of various c-ros retroviral vectors with specific modifications.
  • To determine the role of 5' and 3' modifications in the transforming activity of c-ros.

Main Methods:

  • Construction and study of various c-ros retroviral vectors (Ufcros, Uppcros, CCros, CVros, VCros) with defined genetic alterations.
  • Assessment of cell-transforming and tumorigenic activities in chicken embryo fibroblasts.
  • Analysis of protein tyrosine kinase activity, membrane association, and stability of encoded proteins.

Main Results:

  • VCros, containing 5' v-ros sequences, exhibited potent cell-transforming and tumorigenic activities, similar to UR2.
  • Ufcros, Uppcros, CCros, and CVros were inactive, indicating that specific modifications are required for transformation.
  • Deletion of additional extracellular sequences in CCros and CVros (resulting in CC5d and CV5d) conferred moderate transforming activity, linked to differential substrate interaction.

Conclusions:

  • The 5' modification of c-ros, rather than 3' alterations, is essential for its oncogenic activation.
  • The sequence upstream of the transmembrane domain negatively impacts the transforming activity of CCros and CVros.
  • Deletion of this upstream sequence is necessary to activate the biological transforming activity of c-ros.

Related Concept Videos

Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...